Portal de investigación
Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma.
Fecha de publicación:
Fecha Ahead of Print:
Autores de INCLIVA
Participantes ajenos a INCLIVA
- Gonzalez-Vilanova, A
- Gil, M
- Dura, A
- Richart, P
- Alonso, N
Grupos y Plataformas de I+D+i
Abstract
BACKGROUND: Advanced gastro-oesophageal cancer (GEA) treatment has been improved by the introduction of immune checkpoint inhibitors (CPIs), yet identifying predictive biomarkers remains a priority, particularly in patients with a combined positive score (CPS) < 5, where the benefit is less clear. Our study assesses certain immune microenvironment features related to sensitivity or resistance to CPIs with the aim of implementing a personalised approach across CPS < 5 GEA. DESIGN: Through integrative transcriptomic and clinicopathological analyses, we studied in both a retrospective and a prospective cohort, the immune tumour microenvironment features. We analysed the cell types composing the immune infiltrate highlighting their functional activity. RESULTS: This integrative study allowed the identification of four different groups across our patients. Among them, we identified a cluster whose tumours expressed the most gene signatures related to immunomodulatory pathways and immunotherapy response. These tumours presented an enriched immune infiltrate showing high immune function activity that could potentially achieve the best benefit from CPIs. Finally, our findings were proven in an external CPI-exposed population, where the use of our transcriptomic results combined with CPS helped better identify those patients who could benefit from immunotherapy than using CPS alone (p = 0.043). CONCLUSIONS: This transcriptomic classification could improve precision immunotherapy for GEA.
© 2022. The Author(s).
Datos de la publicación
- ISSN/ISSNe:
- 0007-0920, 1532-1827
- Tipo:
- Article
- Páginas:
- 2198-2206
- PubMed:
- 36253523
BRITISH JOURNAL OF CANCER NATURE PUBLISHING GROUP
Citas Recibidas en Web of Science: 5
Documentos
Filiaciones
Proyectos y Estudios Clínicos
CONTRATOS JUAN RODES
Investigador Principal: DESAMPARADOS RODA PEREZ
2016/197 . INSTITUTO SALUD CARLOS III . 2017
Plataformas biobancos PT17/0015/0049
Investigador Principal: ANTONIO FERRANDEZ IZQUIERDO
PT17/0015/0049 . INSTITUTO SALUD CARLOS III . 2018
Cita
Cabeza M,Gambardella V,Gimeno F,Carbonell JA,Alarcon L,Gonzalez A,Zuniga S,Rentero P,Villagrasa R,Gil M,Dura A,Richart P,Alonso N,Huerta M,Rosello S,Roda D,Tarazona N,Martinez C,Castillo J,Cervantes A,Fleitas T. Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma. Br. J. Cancer. 2022. 127. (12):p. 2198-2206. IF:8,800. (1).
Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma. Cabeza M, Gambardella V, Gimeno F, Carbonell JA, Alarcon L, Gonzalez A, Zuniga S et al. BRITISH JOURNAL OF CANCER. 2022 diciembre 01. 127 (12):2198-2206. DOI:10.1038/s41416-022-02005-z. PMID:36253523.
